Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2
Y Lustig, I Nemet, L Kliker, N Zuckerman… - … England Journal of …, 2021 - Mass Medical Soc
Y Lustig, I Nemet, L Kliker, N Zuckerman, R Yishai, S Alroy-Preis, E Mendelson…
New England Journal of Medicine, 2021•Mass Medical SocVaccination after SARS-CoV-2 Infection Six patients previously infected with the original
SARS-CoV-2 virus received the BNT162b2 vaccine. Before vaccination, they had
neutralizing activity against the B. 1.1. 7 and P. 1 variants but not the B. 1.351 variant. After
one dose, neutralizing activity against all variants increased substantially.
SARS-CoV-2 virus received the BNT162b2 vaccine. Before vaccination, they had
neutralizing activity against the B. 1.1. 7 and P. 1 variants but not the B. 1.351 variant. After
one dose, neutralizing activity against all variants increased substantially.
Vaccination after SARS-CoV-2 Infection
Six patients previously infected with the original SARS-CoV-2 virus received the BNT162b2 vaccine. Before vaccination, they had neutralizing activity against the B.1.1.7 and P.1 variants but not the B.1.351 variant. After one dose, neutralizing activity against all variants increased substantially.
The New England Journal Of Medicine